Last $0.52 USD
Change Today 0.00 / 0.00%
Volume 0.0
ITMMF On Other Exchanges
Tel Aviv
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

itamar medical ltd (ITMMF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/14 - $0.71
52 Week Low
10/8/13 - $0.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ITAMAR MEDICAL LTD (ITMMF)

Related News

No related news articles were found.

itamar medical ltd (ITMMF) Related Businessweek News

No Related Businessweek News Found

itamar medical ltd (ITMMF) Details

Itamar Medical Ltd. develops, markets, and sells diagnostic medical devices. Its medical devices are based on Peripheral Arterial Tone (PAT) signal, a non-invasive window to the cardiovascular system and the autonomic nervous system. The company offers EndoPAT, a medical device for noninvasive endothelial function assessment used in preeminent clinical and research institutions, epidemiological population based studies (such as Framingham Heart Study), and pharmaceutical clinical phase studies; WatchPAT, a medical-grade sleep test for the diagnoses of obstructive sleep apnea, a condition common in metabolic and cardiovascular disease. It also provides companion diagnostic products to support drug discovery and development from inception straight through to regulatory approval and launch. The company was founded in 1997 and is based in Caesarea, Israel.

Founded in 1997

itamar medical ltd (ITMMF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

itamar medical ltd (ITMMF) Key Developments

Itamar Medical Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Itamar Medical Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Itamar Medical Ltd., Special/Extraordinary Shareholders Meeting, Aug 31, 2014

Itamar Medical Ltd., Special/Extraordinary Shareholders Meeting, Aug 31, 2014., at 09:00 Israel Standard Time.

Itamar Medical Ltd. and Nihon Kohden Signs Strategic Marketing and Distribution Agreement for EndoPAT(TM) Device

Itamar Medical Ltd. announced that Nihon Kohden will distribute the EndoPAT(TM) device as their roduct for endothelial function assessment, and will market the EndoPAT(TM) to hospitals and to over 100,000 general practitioners in Japan. The agreement may contribute to Itamar Medical's operations in Japan with sales expected to rise. The exclusive distribution agreement was reached after Nihon Kohden concluded that testing with Itamar Medical's EndoPAT(TM) device provides unique and important indications in assessing the risk of cardiovascular events. The agreement comes a year after Itamar Medical's subsidiary launched operations in Japan, posting steady revenue growth there. The agreement comes on the heels of two strategic marketing agreements concluded with Philips' local representative in Japan and with Medtronic, a giant medical device maker in the United States, both related to Itamar Medical's WatchPAT(TM) acclaimed sleep diagnostic device.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITMMF:US $0.52 USD 0.00

ITMMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITMMF.
View Industry Companies

Industry Analysis


Industry Average

Valuation ITMMF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ITAMAR MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at